MELBOURNE, Australia and NANTES, France, April 16, 2018 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has today announced a research partnership with the French National Institute of Health and Medical Research (Institut national de la santé et de la recherche médicale or “INSERM”) and the “Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantic” (ARRONAX).
Telix Pharmaceuticals, INSERM and ARRONAX Enter into Translational Research Partnership
by GlobeNewsWire | Apr 15, 2018 | Blog